AOD-9604 (AOD)

Metabolic Clinical trials

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH) comprising amino acids 177-191 of the GH molecule with an added tyrosine at the N-terminus. Originally developed by Metabolic Pharmaceuticals in Australia, AOD-9604 was designed to replicate the lipolytic (fat-burning) effects of GH without its growth-promoting or diabetogenic effects. The peptide stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) in adipose tissue. Clinical trials demonstrated significant fat loss without adverse effects on glucose metabolism or IGF-1 levels, distinguishing it from full-length growth hormone.

Key Data

Research Status
Clinical trials
Half-Life
Unknown (short)
Administration
Subcutaneous injection
Typical Dosage
250-500 mcg
Molecular Weight
1,817.1 Da
Molecular Formula
C78H123N23O23S2

Mechanism of Action

Mimics the fat-burning portion of HGH without affecting IGF-1 or insulin. Stimulates lipolysis.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home